Supplier
Community Hospital of Noble County, INC.
Community Hospital of Noble County, INC. was paid $8.47M by Medicaid between Jan 2018 and Nov 2024, across 90 billing codes. Its largest line is 99283, emergency room visit (moderate) — 46% of everything it billed.
33Billing provider infoCOMMUNITY HOSPITAL OF NOBLE COUNTY, INC.
KENDALLVILLE, IN 46755
KENDALLVILLE, IN 46755
33aNPI1457366189assigned 07/30/2006
33bProvider typeInstitutional Pharmacy
28Total paid$8.47M
24GClaims146,263
24DCodes billed90
24AFirst – last monthJan 2018 – Nov 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RISSER, STANTON controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 23,768 | $588K | |
| 2019 | 16,750 | $767K | |
| 2020 | 15,516 | $1.03M | |
| 2021 | 25,769 | $1.78M | |
| 2022 | 30,068 | $1.89M | |
| 2023 | 20,648 | $1.50M | |
| 2024incomplete | 13,744 | $917K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 46% | 22,397 | 19,645 | $3.88M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 10,142 | 8,424 | $1.42M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 11% | 1,780 | 695 | $890K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4.1% | 5,840 | 4,794 | $349K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.1% | 2,110 | 1,916 | $348K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3.3% | 1,320 | 1,090 | $277K |
| 71045 | Radiologic examination, chest; single view | 2.9% | 1,908 | 1,546 | $243K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.6% | 1,971 | 1,709 | $138K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 336 | 281 | $116K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.1% | 3,692 | 3,121 | $96K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 718 | 632 | $74K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 16,800 | 13,551 | $71K |
78 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,397 | $67K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,042 | $61K |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,914 | $32K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 494 | $31K |
| 80050 | General health panel | <1% | 172 | $23K |
| 80076 | <1% | 5,428 | $23K | |
| 80074 | <1% | 534 | $23K | |
| 84484 | <1% | 3,275 | $21K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 307 | $19K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,102 | $18K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,646 | $17K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 206 | $16K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 485 | $16K |
| 80061 | Lipid panel | <1% | 1,598 | $13K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,997 | $11K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 403 | $11K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 80 | $10K |
| 99217 | <1% | 22 | $10K | |
| 83690 | <1% | 3,396 | $10K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 26 | $9K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 580 | $9K |
| 80053 | Comprehensive metabolic panel | <1% | 1,051 | $8K |
| 99219 | <1% | 22 | $8K | |
| 81001 | <1% | 4,549 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 145 | $6K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 14 | $6K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 225 | $6K |
| 83735 | <1% | 1,460 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 456 | $5K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 124 | $5K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 121 | $5K |
| 76801 | <1% | 25 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 355 | $4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 71 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 930 | $4K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 174 | $4K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 30 | $3K |
| 87634 | <1% | 61 | $3K | |
| 81025 | <1% | 500 | $3K | |
| 87522 | Neg quan hep c or qual rna | <1% | 87 | $3K |
| 82607 | <1% | 453 | $3K | |
| 85027 | <1% | 777 | $2K | |
| 86481 | <1% | 30 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 301 | $2K |
| 80055 | <1% | 49 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 118 | $1K |
| 73630 | <1% | 14 | $697.95 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 251 | $590.46 |
| 86803 | <1% | 51 | $514.58 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 14 | $453.60 |
| 80355 | <1% | 12 | $420.00 | |
| 84460 | <1% | 210 | $377.05 | |
| 84450 | <1% | 211 | $374.75 | |
| 84439 | <1% | 120 | $372.56 | |
| 81003 | <1% | 273 | $363.08 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 16 | $272.76 |
| A0429 | Emergency ambulance ride, basic life support | <1% | 964 | $270.00 |
| 85379 | <1% | 31 | $226.04 | |
| 82728 | <1% | 43 | $199.23 | |
| 82962 | <1% | 85 | $154.73 | |
| 83550 | <1% | 43 | $127.87 | |
| 87081 | <1% | 31 | $127.70 | |
| 84703 | <1% | 19 | $116.61 | |
| 83540 | <1% | 43 | $94.75 | |
| 80047 | <1% | 14 | $82.38 | |
| 82947 | <1% | 17 | $57.71 | |
| 86592 | <1% | 28 | $54.79 | |
| 85610 | <1% | 37 | $40.64 | |
| A0425 | Ground mileage, per statute mile | <1% | 3,210 | $15.05 |
| 86850 | <1% | 12 | $5.05 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 473 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 182 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 57 | $0.00 |
| 93041 | 0% | 13 | $0.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 446 | $0.00 |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | 0% | 451 | $0.00 |
| A0427 | Emergency ambulance ride, advanced life support | 0% | 466 | $0.00 |
| A9270 | Non-covered item or service | 0% | 180 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRISSER, STANTON (ACFO)
Parent organizationCOMMUNITY HOSPITAL OF NOBLE COUNTY, INC.
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.